Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma

Oncogenic KRAS mutations are absent in approximately 10% of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) and may represent a subgroup of mPDAC with therapeutic options beyond standard-of-care cytotoxic chemotherapy. While distinct gene fusions have been implicated in KRAS wildty...

Descripción completa

Detalles Bibliográficos
Autores principales: Topham, James T., Tsang, Erica S., Karasinska, Joanna M., Metcalfe, Andrew, Ali, Hassan, Kalloger, Steve E., Csizmok, Veronika, Williamson, Laura M., Titmuss, Emma, Nielsen, Karina, Negri, Gian Luca, Spencer Miko, Sandra E., Jang, Gun Ho, Denroche, Robert E., Wong, Hui-li, O’Kane, Grainne M., Moore, Richard A., Mungall, Andrew J., Loree, Jonathan M., Notta, Faiyaz, Wilson, Julie M., Bathe, Oliver F., Tang, Patricia A., Goodwin, Rachel, Morin, Gregg B., Knox, Jennifer J., Gallinger, Steven, Laskin, Janessa, Marra, Marco A., Jones, Steven J. M., Schaeffer, David F., Renouf, Daniel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547977/
https://www.ncbi.nlm.nih.gov/pubmed/36209277
http://dx.doi.org/10.1038/s41467-022-33718-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547977/
https://www.ncbi.nlm.nih.gov/pubmed/36209277
http://dx.doi.org/10.1038/s41467-022-33718-7

Ejemplares similares